A RAS Inhibitor Is Approved for Pancreatic Cancer: Reading the News Carefully

Pancreatic cancer has had few new treatments for a long time. So any approval gets attention. The FDA keeps a running list of cancer drug approvals. We read it on September 24, 2026. An entry dated August 26, 2026 lists a drug called daraxonrasib (brand name RASONQUE). The list says it blocks a family of proteins called RAS. It is approved for pancreatic cancer that has spread, in people who have already had drug treatment.

Two parts of that are worth a closer look. One is what RAS is. The other is what "previously treated" and "metastatic" mean together.

What the pancreas does, briefly

The National Cancer Institute describes pancreatic cancer as "a type of cancer that forms in the tissues of the pancreas." The pancreas is a gland about six inches long. It has a head, a body and a tail. NCI describes its two jobs as "to make juices that help break down food" and "to make hormones, such as insulin and glucagon, that help control blood sugar levels."

About 95% of pancreatic cancers start in the cells that make those juices. Adenocarcinoma is the name for cancer that starts in these gland cells. That is why the approval says pancreatic adenocarcinoma, not just pancreatic cancer.

What RAS and KRAS are

RAS is a family of proteins inside cells that act like switches for growth signals. KRAS is one member of that family. Sometimes the gene for one of these switches has a change. Then the switch can get stuck "on." The cell keeps getting told to grow.

This matters a lot in pancreatic cancer. NCI's patient page says: "Nine out of ten pancreatic cancers have this mutation, and it is one of the earliest gene changes found as the disease progresses."

That is why RAS has long been both a goal and a frustration. For decades, it was thought to be very hard to aim a drug at. NCI's page also notes that some people could get daraxonrasib before this, through FDA expanded access. That is a route used while a drug is still being studied.

A drug made to block one protein like this is called a targeted therapy. NCI defines that as treatment that "targets proteins that control how cancer cells grow, divide, and spread." NCI also says of pancreatic cancer specifically: "Molecular testing of the tumor is important and can help your doctor decide whether you are a candidate for targeted therapy."

What the approval wording narrows down

Two words in the indication do a lot of work.

Metastatic means the cancer has spread from the pancreas to other parts of the body. Previously treated means this is not a first treatment. The listing calls it "prior systemic therapy." It is for people who have already had drug treatment.

So an approval is not a recommendation. And it is not for everyone with pancreatic cancer.

What this approval cannot tell you

• It cannot tell you how much longer anyone lives. The FDA list records a decision, not survival results. We did not read trial data for this page. So we give no numbers about it.
• It cannot tell you whether it fits a particular person. That depends on the type of cancer, past treatment, tumor test results and overall health. An approval list knows none of these.
• It cannot tell you about side effects. Those are not in the list. They matter as much as how the drug works.
• It cannot tell you this will work. NCI is careful about precision medicine in general: "Biomarker tests don't help everyone who gets them," and even when a matching target is found, "the therapy may not work for you." Cells in one tumor do not all have the same markers. And the picture can change over time.
• It changes nothing about screening or prevention. There is no general screening test for pancreatic cancer. This is a treatment question for people already diagnosed.

What to ask a healthcare team

• Has my tumor had molecular testing, and what did it show about KRAS or RAS?
• Is a drug of this kind relevant to my situation, and at what point?
• What would we be hoping to see, and how soon would we know?
• What are the trade-offs — side effects, visits, monitoring — compared with what I am doing now?
• Are there clinical trials I should know about alongside approved options?

How this article was prepared

An AI-assisted editorial system helped prepare this page. It used the FDA's list of cancer drug approvals. It also used NCI patient pages on pancreatic cancer treatment, targeted therapy and precision medicine. Each was opened on the source-check date shown above. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.